Lonza Agrees to Buy Five Merck U.S. Plants, More Than Doubling Its Footprint
Lonza has signed an agreement to acquire five U.S. manufacturing sites from Merck & Co., known as MSD outside the United States and Canada. The transaction was announced on 3 November 2026 and is expected to close in mid-2027, subject to customary conditions. Until closing, the sites remain part of Merck and operate independently from Lonza.
If completed, the acquisition would expand Lonza's U.S. site count from four to nine, an increase of 125%. About 1,100 employees are expected to transfer, taking Lonza's American workforce above 6,000. The deal is significant less for immediate revenue than for the range of manufacturing technologies and customer capacity it would place inside one contract-development and manufacturing network.
Five sites add different manufacturing capabilities
The assets include bioconjugate manufacturing in St. Louis, Missouri; payload and linker production in Madison and Verona, Wisconsin; viral-vector and fill-finish capacity in Carlsbad, California; and lipid nanoparticle, liposome, PEGylated-protein and fill-finish capabilities in Indianapolis, Indiana. This is not a purchase of five interchangeable factories. It is an assembly of specialized technologies that serve different drug platforms and stages of production.
That breadth can matter to pharmaceutical customers trying to reduce transfers between suppliers. A network spanning active materials, complex delivery systems, viral vectors and sterile filling can shorten technical handoffs if it is integrated successfully. The opposite risk is execution complexity: quality systems, digital infrastructure, customer contracts and regulatory histories must be transferred without disrupting validated production.
The footprint doubles, but near-term sales remain modest
Lonza described the enterprise valuation only as a low- to mid-triple-digit million amount in Swiss francs. It did not disclose an exact price, so assigning a midpoint would create false precision. The company expects the sites to contribute about CHF250 million of sales in 2028 at a margin below the Lonza group level, with an insignificant effect on group profitability at that stage.
The disclosed 2028 sales expectation is therefore a base to develop, not evidence that the acquired sites will immediately transform group earnings. Lonza expects further investment in line with customer demand and says the businesses could reach peak sales and margin contribution in the mid-2030s. Those are forward-looking company targets.
Why the transaction changes competitive capacity
Contract manufacturers compete not only on installed equipment, but on regulatory execution, skilled staff and the ability to move a product from development into commercial production. Acquiring operating sites and 1,100 employees can add capability faster than building greenfield facilities, but the value depends on utilization and customer retention after the transfer.
The transaction also concentrates more U.S. manufacturing capacity within a global CDMO at a time when drug companies are reconsidering supply-chain resilience and regional production. That can create more domestic options for customers. It can also increase dependence on a smaller number of large service providers, making contract terms, capacity allocation and quality performance important for buyers.
Financing and closing risk
Lonza plans to fund the acquisition with cash and available credit facilities and says it expects to maintain its BBB+ rating. Because the exact purchase price and planned capital expenditure are not disclosed, the ultimate leverage and return profile cannot yet be independently calculated.
The long interval to the expected mid-2027 closing leaves room for regulatory review, contract adjustments and integration planning. Employees, customers and suppliers should treat the signed agreement as an important direction of travel, not a completed ownership change.
What to watch
The most useful next disclosures will be the final purchase price, transaction approvals, customer and product-transfer arrangements, retained utilization, site-level investment and the pace at which margins approach the Lonza average. A smooth legal closing is only the first test; maintaining regulated production while integrating five specialized sites is the operational test.
Agrilinkage based this report on Lonza's 3 November transaction announcement. Site count, employee numbers, expected 2028 sales, valuation range and closing timing are company disclosures. The 125% footprint increase is an Agrilinkage calculation from the disclosed move from four to nine U.S. sites. Forward-looking targets are identified as such.
Comments